Orthofix Medical Inc (OFIX) FinancialsOFIXOrthofix Medical Inc

Orthofix Medical Inc. (OFIX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Spinal Implants, accounting for 53.9% of total sales, equivalent to $106.08M. Another important revenue stream is Bone Growth Therapies. Understanding this composition is critical for investors evaluating how OFIX navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Orthofix Medical Inc. maintains a gross margin of 70.97%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -2.02%, while the net margin is -7.49%. These profitability ratios, combined with a Return on Equity (ROE) of -13.91%, provide a clear picture of how effectively OFIX converts its operational activities into shareholder value.

In the context of the broader market, OFIX competes directly with industry leaders such as MOBI and PACB. With a market capitalization of $421.18M, it holds a significant position in the sector. When comparing efficiency, OFIX's gross margin of 70.97% stands against MOBI's 83.21% and PACB's 30.26%. Such benchmarking helps identify whether Orthofix Medical Inc. is trading at a premium or discount relative to its financial performance.

Orthofix reported Q2 2026 revenue of $210.93 million, a 3.8% year-over-year increase, but net income remains negative with a reported EPS of -$0.39. The gross margin is strong at 70.97%, indicating good cost management relative to sales. However, the company has faced liquidity pressures with cash decreasing from $120.9M to $104.4M in Q2 2026.